Protalix BioTherapeutics, Inc. cotiza a 2.78 USD y tiene una capitalización bursátil de $224M. En los últimos 12 meses ha facturado $81M con un margen de flujo de caja libre del -25.8%. Cotiza a 29.2 veces su flujo de caja libre (P/FCF) y a un PER de 11.8. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatm…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $0.05 | $0.22 | $-0.07 |
| Estimado | $-0.02 | $-0.01 | $-0.01 | $0.01 |
| Sorpresa | — | +600.0% | +2300.0% | -800.0% |
| Métrica | PLX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 48.8% | 57.0% | -8.2% |
| Operating Margin | -10.4% | -38.6% | +28.2% |
| Net Margin | -12.5% | -33.6% | +21.0% |
| FCF Margin | -25.8% | -13.9% | -12.0% |
| ROE | -13.7% | -40.4% | +26.7% |
| ROA | -8.0% | -32.0% | +24.0% |
| Current Ratio | 2.51 | 2.84 | -0.33 |
| Debt / Equity | — | 0.28 | — |